| Literature DB >> 30862245 |
Michael Joubert1, Pierre-Yves Benhamou2, Pauline Schaepelynck3, Hélène Hanaire4, Bogdan Catargi5, Anne Farret6, Pierre Fontaine7, Bruno Guerci8, Yves Reznik1, Nathalie Jeandidier9, Alfred Penfornis10, Sophie Borot11, Lucy Chaillous12, Sylvia Franc13, Pierre Serusclat14, Yacine Kherbachi15, Eric Bavière16, Bruno Detournay17, Pierre Simon18, Guillaume Charpentier13.
Abstract
Benefits of telemedicine have been proven in the field of diabetes. Among a number of technical solutions, Diabeo® has been studied in both type 1 and type 2 diabetes with intensive insulin therapy. This digital therapeutic system contains a self-monitoring glucose logbook and offers automated insulin dose recommendations thanks to a fully customizable algorithm. In addition, the cloud-based dedicated software also has features to facilitate remote monitoring, including a platform for diabetes nurses who perform coaching and treatment adjustment. A detailed description of this telemedicine system is provided, as well as results of completed clinical studies. In particular, TeleDiab 1's positive results on HbA1c in type 1 diabetes are detailed. We conclude with a discussion of the role of this telemedicine system within the landscape of mobile apps for diabetes.Entities:
Keywords: insulin therapy; remote monitoring; telemedicine; type 1 diabetes; type 2 diabetes
Mesh：
Substances：
Year: 2019 PMID： 30862245 PMCID： PMC6835183 DOI： 10.1177/1932296819834054
Source DB: PubMed Journal: J Diabetes Sci Technol ISSN： 1932-2968